NCT00942578 2018-10-11A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate CancerNational Institutes of Health Clinical Center (CC)Phase 2 Completed63 enrolled 23 charts